"This man's tumour is destroying his eye. His only NHS option is to have his eyelids sewn shut. This drug could shrink the ...

Vismodegib(Erivedge) generic is a hedgehog pathway inhibitor, prescribed for metastatic basal cell carcinoma that cannot be treated with surgery or radiation. It blocks certain substances in the ...

Induction vismodegib followed by vismodegib-RT was safe and efficacious in phase II study of unresectable basal cell carcinoma (N = 24). This study showed an 83% response rate to combined therapy, ...

Patients will be randomized to receive oral vismodegib in combination with intratumoral injection of SP-002 or vismodegib alone. The primary objective is to determine overall response rate (ORR) for a ...

Meeting Coverage > MHNCS Vismodegib-RT Regimen Achieves High Rate of Disease Control in Head and Neck BCC — Local control in 91% of cases at 1 year in small prospective trial by Charles Bankhead ...

While vismodegib, a hedgehog pathway inhibitor indicated for the treatment of locally advanced basal cell carcinoma (BCC), has a high objective response rate (65%), with a complete response of 32% ...

Vismodegib treatment led to the emergence of population of dormant tumour cells characterized by active Wnt signaling that persists despite continuous drug administration.

Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults. Last reviewed: 22 November 2017 Next review: This guidance will be reviewed if there is new ...

3.13 The company assumed that 67% of patients who progress after having vismodegib never have best supportive care, and that post-progression best supportive care for people who have had vismodegib ...

The drug manufacturer presented no suitable data after expiry of the limitation period. A study on the comparator therapy, which was not presented, raised doubts about the added benefit of vismodegib.